Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This trial studies how well low-dose postoperative corticosteroids (FDA approved) affect patient outcomes (patient reported outcomes, pain medication use, length of stay, major complications, and time to first bowel movement) after thoracic and/or lumbar spine fusion surgery.
PRIMARY OBJECTIVES This study aims to compare patient outcomes (patient reported outcomes, pain medication use, length of stay, major complications, and time to first bowel movement) between subjects that receive either 20 mg of PO prednisone or 1 mL of 4 mg/mL of IV dexamethasone sodium phosphate and a control group.
OUTLINE Participants are patients who elect to participate in the study prior to scheduled thoracic and/or lumbar spine fusion surgery at Oregon Health and Science University. Participants undergo their scheduled spine fusion surgery. After surgery, participants are randomized into either the study drug group or the control (non-treatment) group. If randomized into the study drug group, participants will orally take a daily dose of 20 mg of prednisone (1 mL of 4 mg/mL dexamethasone sodium phosphate if unable to tolerate oral administration) on postoperative days one and two.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Corticosteroid | Experimental | Participants in this group will receive a daily dose of corticosteroids on postoperative day one and two after spine fusion surgery |
|
| Control | No Intervention | Participants in this group will receive no steroids on postoperative day one and two after spine fusion surgery. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prednisone 20 Mg | Drug | 20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group |
|
| Measure | Description | Time Frame |
|---|---|---|
| Morphine equivalent pain medication use over the length of hospitalization | This will be measured by converting the dosage of the pain medication administered to its equivalent dosage of morphine. | From postoperative admission to discharge, up to 4 weeks |
| Length of hospital stay after surgery | This will be measured by taking the total minutes the patient stays in the hospital after surgery from time of admission to time of discharge. | From postoperative admission to discharge, up to 4 weeks |
| Time to first bowel movement in hospital after surgery | This will be measured in the total number of minutes from admission after surgery that it takes for the patient to have their first bowel movement recorded. | From postoperative admission to discharge, up to 4 weeks |
| Number of major complications reported during hospital stay after surgery | This will be measured in the total number of major complications (any) that occur during the hospital stay after surgery. These include, infection, neurological deficit, myocardial infarction, stroke, pneumonia, pulmonary embolism, and bleeding. | From postoperative admission to discharge, up to 4 weeks |
| Morphine equivalent pain medication use over the first 48 hours of hospitalization | This will be measured by converting the dosage of the pain medication administered to its equivalent dosage of morphine. | From postoperative admission to 48 hours after |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Spencer J Smith, BS | Contact | 503-828-7136 | smithsp@ohsu.edu |
| Name | Affiliation | Role |
|---|---|---|
| Jung U Yoo, MD | Department of Orthopaedics and Rehabilitation | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oregon Health and Science University | Portland | Oregon | 97239 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011241 | Prednisone |
| C004180 | dexamethasone 21-phosphate |
| ID | Term |
|---|---|
| D011244 | Pregnadienediols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 |
Not provided
Not provided
Participants are randomized into one of two groups: treatment group vs control (no treatment) group
Not provided
Not provided
Not provided
Not provided
|
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |